The purpose of this study is to determine optimal prophylactic antibiotics administration method in elective laparoscopic colorectal surgery...
Date First Received: July 27, 2007
Last Updated: May 6, 2008
Verified by: Japan Multinational Trial Organization, May 2008
Clinical Trial Phase: Phase 3 | Start Date: September 2007
Overall Status: Recruiting
Estimated Enrollment: 580
Brief Summary
Official Title: “Randomized Controlled Trial of Antibiotic Prophylaxis in Elective Laparoscopic Colorectal Surgery: Oral and Systemic Versus Systemic Antibiotics”
Condition Keyword(s):
Intervention(s):
The purpose of this study is to determine optimal prophylactic antibiotics administration method in elective laparoscopic colorectal surgery.
Study Type: Interventional
Study Design: Prevention, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study
Study Primary Completion Date: May 2010
Detailed Clinical Trial Description
The use of antibiotic prophylaxis in patients who undergo elective colorectal surgery is now accepted universally. But the rout of administration should be systematic, oral, or both is controversial. Furthermore, although many trails have been performed, no trial limited to laparoscopic surgery is performed. We compare 2 approaches - oral and systemic versus systemic antibiotic prophylaxis - in limited to elective laparoscopic colorectal surgery.
Intervention(s) in this Clinical Trial
- Drug: cefmetazole
- Intravenous dose of 1g cefmetazole just before surgery and additional doses every 3hs during surgery
- Drug: kanamycin/metronidazole
- 2 doses of oral kanamycin(1g)/ metronidazole(750mg) administration on the day before surgery with intravenous dose of 1g cefmetazole just before surgery and additional doses every 3hs during surgery
Arms, Groups and Cohorts in this Clinical Trial
- Active Comparator: IV
- Intravenous dose of 1g cefmetazole just before surgery and additional doses every 3hs during surgery
- Active Comparator: Oral/IV
- 2 doses of oral kanamycin(1g)/ metronidazole(750mg) administration on the day before surgery with intravenous dose of 1g cefmetazole just before surgery and additional doses every 3hs during surgery
Outcome Measures for this Clinical Trial
Primary Measures
- Incidence and classification of surgical site infection (SSI)
- Time Frame: Within the first 30 days after surgery
- Time Frame: Within the first 30 days after surgery
Secondary Measures
- Incidence of colitis, other infectious diseases and other postoperative complications.
- Time Frame: Within the first 30 days after surgery
- Time Frame: Within the first 30 days after surgery
Criteria for Participation in this Clinical Trial
Inclusion Criteria:
- Colorectal tumor(cancer, adenoma and suspected cases) with planned elective laparoscopic colorectal resection
Exclusion Criteria:
- ECOG Performance Status >=2
- Age<20
- Any organ dysfunction
- Ileus
- Preoperative infectious disease
- Antibiotic administration before surgery
- Steroid administration before surgery
- Neo-adjuvant radiation and/or chemo therapy
- Severe diabetes mellitus
- Pregnancy/lactational woman
- Severe allergy
Gender Eligibility for this Clinical Trial: Both
Minimum Age for this Clinical Trial: 20 Years
Maximum Age for this Clinical Trial: N/A
Are Healthy Volunteers Accepted for this Clinical Trial?: No
Clinical Trial Sponsor Information
Lead Sponsor: Japan Multinational Trial Organization
Overall Clinical Trial Officials and Contacts
Hiroaki Hata, MD Principal Investigator National Hospital Organization, Kyoto Medical Center
Overall Contact: Hiroaki Hata, MD 81756419161 hhata-kyt@umin.ac.jp
Additional Information
Information obtained from ClinicalTrials.gov on August 28, 2008
Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00508690
Study ID Number: JMTO PREV07-01
ClinicalTrials.gov Identifier: NCT00508690
Health Authority: Japan: Institutional Review Board
UMIN Clinical Trial Registry: Unique trial number UMIN000000776
Clinical Trials Authorship and Review
Clinical Trials content is provided directly by the U.S. National Institutes of Health via ClinicalTrials.gov and is not reviewed separately by ClinicalTrialsFeeds.org. Every page of specific clinical trials information contains a unique identifier which can be used to find further details directly from the National Institutes of Health.